The following video is part of our "Motley Fool Conversations" series, in which advisor Charly Travers and analyst Jason Moser discuss topics around the investing world.

Gilead Sciences is a world-class drug company that has created tremendous value for shareholders with a stock that's up 5 times over the past decade. The company, best known for its work in HIV drug development, is trying to branch out in another important anti-viral market: the treatment of hepatitis C. Gilead's recent clinical trial data on HCV drug GS-7977 was poorly received, sending the stock down 20%. Is now the time to buy?